TRBV21-1: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: TRBV21-1

NCBI ID: G28566

TRBV21-1

Other Name(s): TRBV211 | T cell receptor beta variable 21-1 (pseudogene) | TCRBV21S1 | TCRBV10S1P

TRBV21-1: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a major public health issue, affecting millions of people worldwide. The persistent nature of pain can have a significant impact on an individual's quality of life, and its underlying causes can be difficult to diagnose and treat. The TRBV21-1 gene, located on chromosome 6q21, has been identified as a potential drug target and biomarker for chronic pain.

The TRBV21-1 gene

The TRBV21-1 gene is a non-coding RNA molecule that has been shown to play a role in the regulation of pain signaling pathways. The gene encodes a protein known as TRPV2, which is a key component of the pain receptor. TRPV2 is expressed in various and tissues cells, including neurons, perisarcular muscles, and other pain-sensitive tissues.

Chronic pain is associated with the activation of pain signaling pathways, which can lead to the production of pro-inflammatory cytokines and other signaling molecules. These cytokines can recruit additional immune cells to the site of pain, further exacerbating the pain experience. The TRBV21- 1 gene has been shown to be involved in the regulation of these pain signaling pathways.

Potential drug targets

The TRBV21-1 gene has the potential to serve as a drug target for chronic pain. By inhibiting the activity of TRPV2, drugs can reduce the production of pro-inflammatory cytokines and other signaling molecules associated with chronic pain. This can lead to the reduction of pain symptoms and improve overall quality of life.

The TRBV21-1 gene has been targeted by several drug developers as a potential drug target for chronic pain. One such drug, known as TRBV211, is being developed by a company called \"C Quadrant Bio\" (C Quadrant Bio) to treat chronic low back pain. TRBV211 is a small molecule inhibitor of TRPV2, which has been shown to be involved in the regulation of pain signaling pathways.

Biomarker

The TRBV21-1 gene has also been identified as a potential biomarker for chronic pain. By measuring the expression of TRBV21-1 in pain-sensitive tissues, researchers can monitor the effects of pain treatments and determine the effectiveness of new treatments. This can help Improve the development of new pain treatments, which can benefit patients with chronic pain.

Conclusion

The TRBV21-1 gene has the potential to serve as a drug target and biomarker for chronic pain. By inhibiting the activity of TRPV2, drugs can reduce the production of pro-inflammatory cytokines and other signaling molecules associated with chronic pain. The gene has already been targeted by several drug developers, and further research is needed to fully understand its potential as a drug target and biomarker for chronic pain.

Protein Name: T Cell Receptor Beta Variable 21-1 (pseudogene)

The "TRBV21-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV21-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets